Media

Italian national broadcaster Rai 1 visited CUTISS for a feature on denovoSkin™ as part of Noos – L’avventura della conoscenza, the popular science programme hosted by Alberto Angela. The reportage takes viewers inside CUTISS’ GMP manufacturing facility in Schlieren to explore how denovoSkin™, the personalized, bio-engineered skin graft, is produced from a small sample of a patient’s own healthy skin. CEO Daniela Marino discusses the technology and explains the different production stages, from processing the patient’s skin biopsy and expanding the cells to bio-engineering the dermo-epidermal skin graft. Watch the episode in Italian on RaiPlay here. Newsroom Watch episode

CEO and co-founder Daniela Marino is featured in the summer 2026 edition of Interview by Ringier, the Swiss magazine dedicated to in-depth conversations with personalities from business, science, culture, politics and sport. In the four-page interview, titled “Zweite Haut” (“Second Skin”), Daniela discusses the importance and complexity of human skin, the challenges faced by patients with severe burns, and how CUTISS is developing bio-engineered skin tissue to support both healing and quality of life. She explains how denovoSkin™ is produced from a small biopsy of a patient’s own healthy skin and discusses its potential to reduce scarring and improve function compared with conventional skin grafting approaches. The conversation also explores CUTISS’ work to scale and automate production, as well as Daniela’s journey from scientist to biotech entrepreneur. The interview appears in the June 2026 edition of Interview by Ringier, available exclusively in print (text: Peter Hossli; photography: Joan Minder). Find out more about the current edition here and read the full interview in German here. Newsroom read interview

Swiss online news platform Watson visited CUTISS for an in-depth report on denovoSkin™ and the potential of bio-engineered skin to support patients with severe burn injuries. The video and online report take readers inside CUTISS’ GMP manufacturing facility and explains how personalized skin grafts are produced from a small sample of a patient’s own healthy skin. It also explores the challenges of treating extensive burns, the importance of reducing scarring and donor-site requirements, and CUTISS’ work to automate the manufacturing process. Watson spoke with CEO Daniela Marino as well as Production Team Lead Miralda Jusmani, Regulatory Affairs Manager Arina Löw, and Team Leader Quality Control Alexandra Hugo, and looks at the clinical development of denovoSkin™, which is currently being evaluated in a Phase 3 clinical trial for severe burns in Switzerland and the European Union. Watch and read the full Watson reportage in German here. Newsroom Reportage

Swiss newspaper Neue Zürcher Zeitung (NZZ) has featured CUTISS and denovoSkin™ in an in-depth report on the challenges of treating patients with severe burns and the development of laboratory-engineered skin. Published in NZZ’s Forschung und Technik section, the article examines the limitations of conventional split-thickness skin grafting and traces the evolution of cultured skin technologies over several decades. The report highlights CUTISS’ approach to bio-engineering personalized dermo-epidermal skin grafts comprising both an epidermal and dermal component, and looks at the clinical development of denovoSkin™. CUTISS CEO Daniela Marino also discusses the potential of denovoSkin™ to improve scar quality and function for patients with severe burns. The article references recently published clinical data indicating better outcomes with denovoSkin™ compared with conventional split-thickness skin grafting. Read the full NZZ article in German here. Newsroom Article

German lifestyle magazine Brigitte has profiled our CEO Dr. Daniela Marino in its Macherinnen (female makers) section. Under the title “Meisterin der zweiten Haut” (Master of the second skin), the article retraces her journey from early research at Kinderspital Zürich to the founding of CUTISS and the development of our bio-engineered skin substitute, denovoSkin™. The feature highlights how denovoSkin™ is designed to permanently treat severe burns and large skin defects, sparing donor sites, reducing scarring, and growing with children – bringing new hope to “burn survivors”. You can read the full article as a PDF via the link below. Newsroom Article as PDF

Dutch media have reported on the treatment of the first baby with denovoSkin™, in the Netherlands, outside of clinical trials. The operation was performed by doctors and surgeons at the Burn Centre of the Maasstad Hospital in Rotterdam. Trauma and burn surgeon, Kees van der Vries, described the use of denovoSkin™ a “godsend”. “The baby has been successfully operated on and is recovering well. We are proud to have been able to use this treatment. It really makes a difference for patients with severe, large/extensive burns and contributes to a better quality of life. This innovative method offers promising prospects for the future of burn care.” CUTISS is already running clinical trials, including the ongoing Phase 3 study, in the Netherlands at the Brandwondencentrum Beverwijk. The English language media article is available in the NL Times here, and the original Dutch media article can be read in AD here. The Maasstad Hospital has also published its own article regarding the operation which can be found here. Newsroom Article NL Times

As part of his European tour and trip to Switzerland, BiotechTV host Brad Loncar visited CUTISS to learn more about our work in personalized skin tissue therapy. In this interview, our CEO Dr. Daniela Marino shares insights into the development of denovoSkin™, its clinical progress, and the vision behind advancing skin surgery through bioengineering and automation. Watch the full feature on BiotechTV in the link below. Newsroom Watch feature

Our CEO Daniela Marino has been featured in a new entrepreneurship series launched by Schweizer Monat, the Swiss monthly magazine. In her video interview, she discusses the challenges and rewards of leading CUTISS and our mission to transform skin surgery with denovoSkin™, the bio-engineered skin graft which promises to grow with the patient, minimize scarring and improve quality of life, particularly for children. Daniela also shares candid insights on what it takes to innovate in the biotech space, the importance of resilience, and how balancing her professional and personal life keeps her grounded. You can watch and listen to the interview, in German, here.   Newsroom Video Interview

“The start-up hype of recent years has seen many young entrepreneurs come and go. One who has not only made headlines but also delivered results is Daniela Marino.” Thus reads the opening line of the article published in Switzerland’s business newspaper HandelsZeitung. The article was published on the back of our news in October 2024, announcing the first reconstructive surgery that was done under compassionate use and the first U.S. patient treated with denovoSkin™. Having interviewed Jeremy Goverman M.D. at Massachusetts General Hospital and our CEO Daniela Marino,  the journalist recounts the challenges that we overcame in transporting the personalized skin grafts from Schlieren to Boston, and the wonderful positive outcomes that the surgeons are seeing with the young patient in question. “Daniela and her team are trying to do something that no one else in burn medicine is daring to do. She is developing real skin, not just a substitute,” Jeremy Goverman M.D. is quoted as saying. The link to the article, in German, is available here or on PDF. Newsroom Article (PDF)

Panorama, one of Italy’s leading weekly magazines covering current affairs, culture, and technology, has highlighted Switzerland’s emergence as a global leader in biotechnology, artificial intelligence, and cutting-edge innovation, calling it a “new Silicon Valley”. The article highlights the country’s commitment to advancing science and technology and its ability to foster groundbreaking companies that shape the future of healthcare and beyond. CUTISS is proudly featured as an example of innovation in regenerative medicine and skin tissue engineering. The piece emphasizes our pioneering work in developing the world’s first machine capable of bioengineering personalized human skin grafts, the denovoSkin™, for patients suffering from severe skin injuries. Read the full article in Panorama HERE Newsroom Link to article